GERMANTOWN, Md. & HILDEN, Germany–(BUSINESS WIRE)–QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the fast and easy-to-use QIAreach® Anti-SARS-CoV-2 Total Test.
{iframe}https://www.businesswire.com/news/home/20210512005959/en/QIAGEN-Receives-U.S.-FDA-Emergency-Use-Authorization-for-Fast-and-Easy-to-Use-Digital-Test-to-Detect-SARS-CoV-2-Coronavirus-Antibodies{/iframe}